3-氟-4-氨基苯甲酸 | 455-87-8

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟-4-氨基苯甲酸
• 中文别名: 4-氨基-3-氟苯甲酸；4-氨基-3-氟苯酸
• 英文名称: 4-amino-3-fluorobenzoic acid
• 英文别名: 3-fluoro-4-aminobenzoic acid；3-Fluor-4-amino-benzoesaeure
• CAS: 455-87-8
• 化学式: C₇H₆FNO₂
• mdl: MFCD01660374
• 分子量: 155.129
• InChiKey: JSKXHTHMCCDEGD-UHFFFAOYSA-N

物化性质

• 熔点：
  215-218°C
• 沸点：
  320.8±27.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)
• 溶解度：
  溶于热水
• 稳定性/保质期：

  按规格使用和贮存，不会发生分解。应避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封保存，放置于通风、干燥的地方，避免与其它氧化物接触。

SDS

4-Amino-3-fluorobenzoic Acid Revision number: 1
SAFETY DATA SHEET

---

Section 1. BASE INFORMATION
Product name: 4-Amino-3-fluorobenzoic Acid

Revision number: 1

---

Section 2. HAZARDS IDENTIFICATION
Classification of the GHS
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS
Category 2
Skin corrosion/irritation
Serious eye damage/eye irritation Category 2A
Not classified
ENVIRONMENTAL HAZARDS
GHS label elements
Pictograms or hazard symbols
Signal word Warning
Hazard statement Causes skin irritation
Causes serious eye irritation
Precautionary statements
[Prevention] Wash hands thoroughly after handling.
Wear protective gloves/eye protection/face protection.
[Response] IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/attention.
IF ON SKIN: Gently wash with plenty of soap and water.
If skin irritation occurs: Get medical advice/attention.
Take off contaminated clothing and wash before reuse.

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Component(s): 4-Amino-3-fluorobenzoic Acid
Percent: >98.0%(LC)(T)
CAS Number: 455-87-8
Chemical Formula: C7H6FNO2

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. If skin irritation or rash occurs: Get medical advice/attention.
4-Amino-3-fluorobenzoic Acid

---

Section 4. FIRST AID MEASURES
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
Protection of first-aiders: A rescuer should wear personal protective equipment, such as rubber gloves and air-
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Dry chemical, foam, water spray, carbon dioxide.
Suitable extinguishing
media:
Specific hazards: Take care as it may decompose upon combustion or in high temperatures to
generate poisonous fume.
Specific methods: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use personal protective equipment. Keep people away from and upwind of spill/leak.
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Storage
Keep container tightly closed. Store in a cool and dark place.
Storage conditions:
Store away from incompatible materials such as oxidizing agents.
Law is followed.
Packaging material:

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Form: crystal - powder
Color: White - Slightly pale reddish yellow
Odor: No data available
pH: No data available
Melting point/freezing point:No data available
Boiling Point/Range: No data available
4-Amino-3-fluorobenzoic Acid

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Flash Point: No data available
Explosive limits
Lower: No data available
No data available
Upper:
Density: No data available
No data available
Solubility:

---

Section 10. STABILITY AND REACTIVITY
Stability: Stable under proper conditions.
Reactivity: No special reactivity has been reported.
Incompartible materials: oxidizing agents
Hazardous Decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx), Hydrogen fluoride
Products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: ivn-mus LD50:100 mg/kg
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
IARC = No data available
No data available
NTP =
Reproductive toxicity: No data available
DG2525000
RTECS Number:

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobillity in soil
log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
UN-No: Not Listed

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26,
2002): Safe use and production, the storage of a dangerous chemical, transport, loading and unloading were
prescribed.
4-Amino-3-fluorobenzoic Acid

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

合成制备方法

暂无相关信息。

用途

暂无相关信息。

反应信息

• 作为反应物：
  描述：

  3-氟-4-氨基苯甲酸 在 硫酸 、 sodium nitrite 、 sodium azide 作用下， 以 水 为溶剂， 反应 1.67h， 以90%的产率得到4-azido-3-fluorobenzoic acid
  参考文献：
  名称：

  磷酰胺芥末作为前列腺素特异性抗原激活的前药的肽缀合物的设计与合成

  摘要：

  设计并合成了一系列Glutaryl-Hyp-Ala-Ser-Chg-Gln-4-氨基苄基磷酰胺芥末共轭物（1a – e），作为PSA在前列腺癌细胞中进行位点特异性激活的潜在前药。发现所有缀合物都是PSA的底物，在Gln和对氨基苄基（PAB）接头之间发生裂解。对这些结合物的结构-活性关系研究表明，在PAB接头的苯环上引入吸电子的氟均匀地改善了结合物的化学稳定性，而取代位置对结合物的自焚过程产生了不同的影响。蛋白水解。在邻位引入氟如在1b中对苄基磷酰胺的位置导致缀合物在活化之前具有更好的稳定性，同时在被PSA活化时保持其抗增殖活性。具有2-氟取代基的缀合物1b被确定为在前列腺癌靶向前药开发中进行进一步评估和优化的有前途的先导。

  DOI：

  10.1016/j.bmc.2016.04.035
• 作为产物：
  描述：

  3-氟-4-氨基苯腈 在 硫酸 作用下， 生成 3-氟-4-氨基苯甲酸
  参考文献：
  名称：

  一种3-氟-4-硝基苯甲酸的制备方法

  摘要：

  本发明涉及有机化学领域，特别是涉及一种3‑氟‑4‑硝基苯甲酸的制备方法，所述制备方法包括如下步骤：将3,4‑二氟苯腈与氨基取代试剂进行氨基取代反应，以使4位氟被氨基取代，通过短蒸或者精馏的方法将溶剂和4‑氨基‑3‑氟苯腈分离，将4‑氨基‑3‑氟苯腈与氰基水解试剂混合发生氰基水解反应，然后将氰基水解反应得到的水解产物体系与氧化试剂混合进行氰基水解反应，反应后经过后处理得到3‑氟‑4‑硝基苯甲酸，本申请的3‑氟‑4‑硝基苯甲酸的制备方法生产过程简洁、原子利用率高、安全性高、成本低、三废少。

  公开号：

  CN117447327A

文献信息

• Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer
  作者：Xin Wang、Chenhua Yu、Cheng Wang、Yakun Ma、Tianqi Wang、Yao Li、Zhi Huang、Manqian Zhou、Peiqing Sun、Jianyu Zheng、Shengyong Yang、Yan Fan、Rong Xiang

  DOI：10.1016/j.ejmech.2019.07.038

  日期：2019.11

  highly potent, selective CDK9 inhibitors with cancer stem cells (CSCs) inhibition activity were designed and synthesized for non-small-cell lung cancer (NSCLC) therapy. Structure-activity relationship analysis based on enzymatic and cellular activities led to the discovery of a promising inhibitor 21e. 21e potently inhibited CDK9 with IC50 value of 11 nM and suppressed the stemness properties of NSCLC

  设计并合成了一系列具有癌症干细胞（CSCs）抑制活性的新型，高效，选择性CDK9抑制剂，用于非小细胞肺癌（NSCLC）治疗。基于酶和细胞活性的结构-活性关系分析导致发现有前途的抑制剂21e。21e有效抑制CDK9，IC50值为11 nM，并有效抑制NSCLC的干性。它可以降低NSCLC细胞的干细胞表型，包括肿瘤球的形成，侧群和干细胞标志物的丰度。21e显示了对CDK家族激酶的良好选择性，以及针对381个激酶的激酶谱分析。此外，21e抑制了NSCLC中的细胞增殖，集落形成和细胞周期进程并诱导了细胞凋亡。在H1299异种移植小鼠模型中，每天一次剂量为20 mg / kg的化合物21e可以显着抑制肿瘤的生长，而没有明显的毒性。作用机制的研究表明21e在体外和体内均有效抑制CDK9信号传导途径和干性。总体而言，21e作为具有CSCs抑制特性的新型CDK9抑制剂可能是治疗NSCLC的有前途的药物。
• Synthesis, Molecular Docking Analysis and Biological Evaluations of Saccharide-Modified Thiadiazole Sulfonamide Derivatives
  作者：Zuo-Peng Zhang、Ye Zhong、Zhen-Bin Han、Lin Zhou、Hua-Sheng Su、Jian Wang、Yang Liu、Mao-Sheng Cheng

  DOI：10.3390/ijms22115482

  日期：——

  A series of saccharide-modified thiadiazole sulfonamide derivatives has been designed and synthesized by the “tail approach” and evaluated for inhibitory activity against carbonic anhydrases II, IX, and XII. Most of the compounds showed high topological polar surface area (TPSA) values and excellent enzyme inhibitory activity. The impacts of some compounds on the viability of HT-29, MDA-MB-231, and MG-63 human cancer cell lines were examined under both normoxic and hypoxic conditions, and they showed certain inhibitory effects on cell viability. Moreover, it was found that the series of compounds had the ability to raise the pH of the tumor cell microenvironment. All the results proved that saccharide-modified thiadiazole sulfonamides have important research prospects for the development of CA IX inhibitors.

  一系列糖苷修饰的噻二唑磺胺衍生物已通过“尾部方法”设计和合成，并针对碳酸酐酶II、IX和XII的抑制活性进行评估。大多数化合物显示出较高的拓扑极性表面积（TPSA）值和优秀的酶抑制活性。一些化合物对HT-29、MDA-MB-231和MG-63人类癌细胞系的存活率在常氧和低氧条件下进行了检查，它们显示出一定的细胞存活抑制作用。此外，发现这一系列化合物具有提高肿瘤细胞微环境pH值的能力。所有结果证明，糖苷修饰的噻二唑磺胺具有重要的CA IX抑制剂开发研究前景。
• HALO-SUBSTITUTED PYRIMIDODIAZEPINES
  申请人：Cai Jianping

  公开号：US20090318408A1

  公开（公告）日：2009-12-24

  The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

  本发明提供了公式I的PLK1抑制剂化合物： 用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的配方可能在治疗或控制实体肿瘤方面有用，例如乳腺癌、结肠癌、肺癌和前列腺癌等固体肿瘤，以及非霍奇金淋巴瘤等其他肿瘤性疾病。还提供了在合成公式I化合物中有用的中间体化合物。
• 作为Hedgehog信号传导的嘧啶胺类和吡啶胺 类抑制剂
  申请人：江苏先声药业有限公司

  公开号：CN103864770B

  公开（公告）日：2019-06-11

  本发明涉及作为Hedgehog信号传导的嘧啶胺类和吡啶胺类抑制剂，其为具式（I）结构的化合物或其药学上可接受的盐，本发明还涉及这些化合物可以作为hedgehog信号传导抑制剂的医药用途。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE NLRP
  申请人：IFM TRE INC

  公开号：WO2019023147A1

  公开（公告）日：2019-01-31

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一方面，特征在于公式AA的化合物，或其药用可接受的盐。公式AA中所示的变量如权利要求中所定义。公式AA的化合物是NLRP3活性的调节剂，因此，可用于治疗代谢紊乱（例如2型糖尿病、动脉硬化、肥胖或痛风）、中枢神经系统疾病（例如阿尔茨海默病、多发性硬化症、肌萎缩侧索硬化症或帕金森病）、肺病（例如哮喘、慢性阻塞性肺病或特发性肺纤维化）、肝病（例如非酒精性脂肪肝炎、病毒性肝炎或肝硬化）、胰腺病（例如急性胰腺炎或慢性胰腺炎）、肾病（例如急性肾损伤或慢性肾损伤）、肠病（例如克罗恩病或溃疡性结肠炎）、皮肤病（例如银屑病）、肌肉骨骼疾病（例如硬皮病）、血管障碍（例如巨细胞动脉炎）、骨骼疾病（例如骨关节炎、骨质疏松症或骨石化病）、眼病（例如青光眼或黄斑变性）、由病毒感染引起的疾病（例如HIV或艾滋病）、自身免疫病（例如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。

表征谱图